Haemoglobin response to subcutaneous versus intravenous epoetin alfa administration in iron-replete haemodialysis patients.

Nephrology (Carlton) 2004 Jun;9(3):153-60

Department of Nephrology, Royal Melbourne Hospital, Melbourne, Victoria, Australia.

Background: Numerous prior studies have reported that a substantially higher dose of epoetin is required to maintain haemoglobin (Hb) concentration when patients are switched from a subcutaneous (s.c.) to intravenous (i.v.) route of administration. Many of the reported trials, however, involved patients who did not have adequate serum iron levels. It was hypothesized that patients with adequate iron stores who are switched from one route of administration to the other without a change in dose will experience substantially less change in their Hb concentration.

Methods: Haemodialysis patients who were iron replete (ferritin 300-800 microg/L, transferrin saturation (TSAT) 25-50%) participated in a prospective, randomized cross-over trial receiving epoetin for 3 months either by s.c. or i.v. injection followed by a further 3 months of epoetin via the other route. The principal aim was to determine changes in Hb concentration without altering the weekly epoetin dose. The secondary aim was to assess whether the frequency of dosing (once, twice or thrice weekly) influenced the Hb concentration response.

Results: Eighty-one patients (mean age 62 years, 60% male) entered the study and 15 withdrew prior to study completion. Forty-three patients began s.c. epoetin alfa administration (group A) and 38 on i.v. (group B). Median ferritin and TSAT at entry for groups A and B were 409 and 394 microg/L (NS) and 31 and 32% (NS), respectively, which remained within the target range during the study. Median epoetin doses for groups A and B were similar (90 vs 93 IU/kg per week, NS). After 3 months, the mean Hb concentration rose for group A (SC; 118.7-121.9 g/L (P = 0.03)) but it fell for group B (i.v.; 119.1-116.0 g/L (P = 0.019)). Following the change in route of administration, the Hb concentration for group A (i.v.) fell by 5.1% over 3 months (121.9-115.4, P < 0.001) and rose by 2.8% for group B (s.c.) over 3 months (116.0-119.7, P = 0.001). Similar significant changes in the Hb concentration were seen at different dosing frequencies.

Conclusion: Subcutaneous administration of epoetin produces a significant, although slight clinical change in Hb concentration compared with i.v. administration in stable, iron replete, haemodialysis patients. A similar effect appears to prevail regardless of the frequency of injections given.

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1440-1797.2004.00251.xDOI Listing
June 2004
14 Reads

Publication Analysis

Top Keywords

haemodialysis patients
12
route administration
12
patients
8
epoetin
8
alfa administration
8
iron replete
8
changes concentration
8
epoetin alfa
8
patients adequate
8
administration
7
concentration
7
group
6
months
5
assess frequency
4
g/l 003
4
determine changes
4
aim determine
4
fell group
4
principal aim
4
003 fell
4

References

(Supplied by CrossRef)

Ma JZ et al.
J. Am. Soc. Nephrol. 1999

Xia H et al.
J. Am. Soc. Nephrol. 1999

Foley RN et al.
Am. J. Kidney Dis. 1996

Levin A et al.
Am. J. Kidney Dis. 1996

Pickett JL et al.
Am. J. Kidney Dis. 1999

Schaefer RM et al.
Clin. Nephrol. 1989

Besarab A et al.
J. Am. Soc. Nephrol. 1992

Schaller R et al.
Artif. Organs 1994

Paganini EP et al.
Am. J. Kidney Dis. 1995

Similar Publications